UNSPSC 51433706: Treprostinil sodium

This classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula C23H33O5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JZ75N2NT6, chemically known as acetic acid, (((1r,2r,3as,9as)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3s)-3-hydroxyoctyl)-1h-benz(f)inden-5-yl)oxy)-, monosodium salt but more generally known as treprostinil sodium, which bears US NIH Compound Identifier 130880.

UNSPSC 51433706 Treprostinil sodium (Commodity) represents a specialized pharmaceutical product that state and local governments procure primarily through emergency medical services and health plan pharmacy benefit programs. Recent solicitations show this code capturing not only treprostinil itself but also related branded and generic medications acquired as part of broader pharmaceutical bundles for emergency response, state health commission initiatives, and cooperative purchasing alliances. The work involves supplying regulated pharmaceutical products with strict expiration-date management, manufacturing compliance certifications, and OSHA-compliant safety documentation. Issuing bodies span city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing organizations administering contracts on behalf of member state agencies and local governments.

The City of Tampa's Fire Rescue department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—a bundle including epinephrine, adenosine, labetalol, and diltiazem—with a $40,000 estimated contract value and an April 8, 2026 response date; the solicitation carried a Small Local Business Enterprise set-aside with a 5 percent bid discount capped at $10,000. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs and vendor capabilities for state pharmacy benefit management outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products requiring compliance with cGMP and Drug Supply Chain Security Act standards, with an March 26, 2026 response deadline and July 1, 2026 contract effective date. Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative model extending reach across multiple states including Oregon.